that suggest a new diagnostic or therapeutic approach. Nevertheless, it should be emphasized that for most of these disorders, genes within the major histocompatibility complex (MHC) have by far the strongest single genetic effect, and many of these associations have been known for decades. 27 It is likely that most of these genetic associations reflect the immunoregulatory effects of the HLA molecules themselves, although the exact mechanisms that underlie these effects are still a matter of some debate. Therefore, although the MHC is not a major focus of our discussion, the new genetic findings in autoimmunity must always be considered in the context of the important contributions of the HLA complex to disease susceptibility and pathogenesis.
Au t oim muni t y -A C ompl e x Qua n t i tat i v e T r a i t
The original idea of autoimmunity derives from Paul Ehrlich's realization that a functional immune system must have "horror autotoxicus," which he conceived as having "certain contrivances" that would prevent immune attack against the self. 28 Recent genetic findings emphasize that these "contrivances" are multiple and complex. Several decades of increasingly sophisticated basic immunologic studies in mice have provided an elegant platform for interpretation of the genetic data and hypothesis generation. It is convenient to divide the immune system into innate and adaptive systems, although in reality they are highly integrated and interdependent. The innate immune system is phylogenetically older and is designed for immediate engagement of pathogens by a highly conserved set of pattern-recognition receptors, such as toll-like receptors, coupled with a prompt defensive response by the cell. In contrast, the adaptive immune system consists primarily of T and B cells, which use highly diverse receptor systems selected somatically for antigen recognition (T-cell receptor and surface immunoglobulin, respectively) that can recognize millions of distinct foreign antigens, and by the formation of immunologic memory. This immediately raises the problem of selecting functional receptors that do not lead to uncontrolled self-reactivity. Self-reactive B and T cells are a normal component of the immune system, but they are kept in check by a variety of mechanisms, many of which appear to be altered by genetic loci implicated in autoimmunity (Fig. 1) . Some are central mechanisms in the thymus and bone marrow that delete or disable self-reactive clones; others are peripheral and include specialized regulatory cells, such as regulatory T cells. 29 Several mendelian disorders directly illustrate the importance of these mechanisms. For example, mutations affecting the transcription factor autoimmune regulator lead to a relaxing of selection against self-reactivity by T cells in the thymus, giving rise to a rare, aggressive autoimmune disease, autoimmune polyendocrine syndrome 1. 30 The autoimmune regulator controls the ectopic expression of self-antigens within the thymus 31 and thus is critical to the negative selection of T cells reactive with these antigens. Genetic studies indicate the presence of more limited defects in selection against reactivity with self-antigens, such as insulin, in the predisposition to type 1 diabetes. 3 In contrast to these defects in central tolerance, a loss of the FOXP3 transcription factor in the mendelian disorder IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) 32, 33 causes aggressive autoimmunity as a result of defects in the function of regulatory T cells. A milder defect in the regulatory activity of such cells may be caused by quantitative changes in the expression of CD25 (IL2RA), 34 encoding the receptor for interleukin-2, a cytokine that is critical to the survival of regulatory T cells and that such cells cannot produce themselves. 29 Analogous control mechanisms are active at numerous checkpoints in the B-cell portion of the immune system 35 (Fig. 1) . For example, pre-B cells in the bone marrow are highly autoreactive but become less so on differentiation into naive B cells in the periphery, a process that is influenced by the gene encoding protein tyrosine phosphatase nonreceptor type 22 (PTPN22) and other genes associated with autoimmunity. 36 Overall, these processes of selection and regulation of T and B cells are controlled by cell-signaling events that are normally active within a range of potency that may vary among persons and Selection against self-reactivity in developing T cells occurs in the thymus, where more than 98% of developing thymocytes die from apoptosis because of excessive reactivity to self-peptides bound to major histocompatibility complex (MHC) molecules, followed by positive selection for functionally competent effector T cells (CD4+ and CD8+) that are released into the periphery. The expression of self-antigens in the thymus is genetically regulated by transcription factors, such as autoimmune regulator, or by genetic variation in self-antigens themselves (e.g., insulin). The production of peripheral regulatory T cells (Tregs) is also under genetic control, exemplified by the transcription factor FOXP3, the absence of which leads to severe autoimmunity. Alterations in genes affecting these various pathways may lead to quantitative as well as qualitative differences in the potential for self-reactivity of the repertoire of mature T-cell receptors (TCRs). An analogous process of selection against self-reactivity by B cells occurs in the bone marrow, where self-reactivity is dramatically reduced as B cells transition out of the bone marrow into the peripheral B-cell population. Peripheral mechanisms for preventing self-reactivity also exist. In this context, Tregs play a key role in T cells, where genetic alterations in interleukin-2 pathways may influence the efficiency of Treg regulation. Multiple additional peripheral mechanisms contribute to keeping the immune response under control during the activation of both B and T cells in the peripheral immune system, including extensive cross-talk between T cells and B cells, as well as interactions with the innate immune system (not shown).
The among cell types, owing in large part to genetic or epigenetic diversity in the population. This leads to a general concept of immune responsiveness and regulation as a trait that exists on a continuum (a quantitative trait), setting thresholds for cell activation and response. 37 Indeed, the original discovery of the MHC, which encodes HLA, as a locus controlling immune responses was described as a quantitative trait -HLA-regulated immune responses are generally high or low, as opposed to just absent or present (Fig. 2) . For example, given an antigenic stimulus of a given strength (say, presentation of self-antigen by self-HLA in the thymus), responsiveness can vary among persons. Such variability can result in more or less efficient signaling in the T-cell receptor, leading in turn to apoptosis and negative selection over a range of self-reactivity. These events directly influence the diversity of the mature T-cell repertoire after thymic selection is complete. Similar quantitative effects are likely to be operating in cytokine pathways 34 and in many signaling pathways in both the adaptive and innate systems of the immune system.
In t r acel lul a r Signa l ing Path wa ys
Many of the genes that have recently been implicated in autoimmunity contribute to immune signaling pathways involving T-cell and B-cell receptors, costimulatory molecules and cytokines, and pattern-recognition receptors, such as toll-like receptors or nucleotide-binding oligomerization domain (NOD) receptors that are involved in innate immune responses. Although the exact causative alleles are not known in most cases, there are some exceptions. For example, the causative change in the intracellular phosphatase PTPN22 is almost certainly due to a specific amino acid substitution (of arginine by tryptophan) at position 620 of the protein. This amino acid change disrupts binding between PTPN22 and an intracellular kinase called Csk (Fig. 3) , and this in turn alters the responsiveness of both T and B cells to receptor stimulation. Mice lacking Ptpn22 have dramatically increased T-cell activation. 38 Recent data indicate that a similar phenotype of enhanced lymphocyte responsiveness is associated with the PTPN22 risk allele, 39, 40 although data from humans continue to conflict. 41, 42 In any case, there is little doubt that alterations in PTPN22 change the thresholds for receptor signaling by T and B cells; the mechanism by which they lead to autoimmunity remains unclear. Furthermore, the consequences of a specific variant may be different for various diseases. For example, the PTPN22 620 tryptophan risk allele confers an increased risk of a variety of humoral autoimmune disorders, such as rheumatoid arthritis, thyroid disease, type 1 diabetes, and many others, 43 but protects against Crohn's disease. 6 At the same time, it has no effect on the risk of multiple sclerosis. 44 This same allele also appears to influence the outcome for certain infectious diseases. 45, 46 Thus, the genetics of PTPN22 shows the profound effect of subtle changes in intracellular-signaling thresholds on individual disease susceptibility. 43 The precise causative variations that have the greatest effect on other intracellular-signaling pathways involved in autoimmunity are much less clear than for PTPN22, and in some cases the new genetic findings have focused attention on newly emerging signaling mechanisms. A good example of this concerns the role of protein ubiquitination. Analogous to protein phosphorylation, the addition and removal of ubiquitin from proteins is a Cells of the adaptive immune system are selected for stimulus-response characteristics over a range of values, and these may differ for different individuals or for different cells, depending in part on genetic or other host factors that influence receptor signaling pathways. This can lead to individual variation in the overall thresholds of activation for a diverse array of immune stimuli and effector responses, with associated susceptibility or resistance to autoimmune disease. These threshold effects have been most clearly shown for thymic and early B-cell selection events, but it is likely that individual variation in stimulus-response characteristics influences many signaling systems relevant to autoimmunity. BCR denotes B-cell receptor, and TCR T-cell receptor.
The common means of regulating immune signaling pathways. 47 Several of the genes associated with autoimmunity have a role in regulating ubiquitination (TNFAIP3), binding to ubiquitinated proteins (TNIP1 and UBASH3A), or regulating enzymatic events in ubiquitination (UBE2L3) ( Table 1) .
A large number of the signaling pathways that are implicated in autoimmunity have a component of ubiquitin-mediated regulation. 47 This area of investigation is likely to dramatically expand our understanding of autoimmune mechanisms in the coming years. After a T-cell receptor (TCR) is triggered by a peptide and major histocompatibility complex (MHC), one of the earliest events is activation of lymphocyte-specific protein tyrosine kinase (Lck) by removal of an inhibitory phosphate (phospho Y505) by membrane phosphatase CD45 and autophosphorylation of Lck at phospho Y394, as shown at the left of the figure. These events convert Lck to an active state, in which it can phosphorylate substrates, such as 70-kD zeta-associated protein (ZAP-70) and immunoreceptor tyrosine-based activation motif in the TCR complex itself. The risk allele of PTPN22 encodes an amino acid substitution (Arg620Trp) that disrupts binding between PTPN22 protein and c-src tyrosine kinase (Csk). This disruption may either lower or increase the activation state of Lck, depending on the experimental situation. A number of distinct downstream signaling pathways are regulated by Lck-ZAP-70 signaling, including the activation of kinases, such as mitogen-activated protein kinase 8 (MAPK8, or JNK) and MAPK p38 and extracellular signal-related kinase 1 and 2 (ERK1/2), activation of nuclear factor κB (NF-κB) through protein kinase C theta (PRKCQ), as well as calcium release and cytoskeletal reorganization. Genetic variants affecting CD45, PRKCQ, and c-Rel have also been associated with autoimmune diseases, which emphasizes that multiple variants may contribute to subtle variation in signaling thresholds. A role for costimulatory molecules in T-cell activation is also indicated at the right of the figure. In this case, genetic variation affecting a negative regulator of T-cell activation (e.g., CTLA4) can alter lymphocyte responses and predispose to autoimmunity. Many other such costimulatory molecules (not shown) have been revealed as potential regulators of autoimmunity in genetic studies (see Table 1 ). DAG denotes diacylglycerol, IP3 inositol triphosphate, and PLC-γ phospholipase C-γ. Asterisks indicate gene products for which genetic associations with autoimmunity have been documented.
The 
Gene t ic Va r i at ion a nd C y t ok ine Path wa ys
Given the central role of modulation of cytokine function in the development of new treatments for autoimmunity, it is not surprising that many of the strongest genetic associations have implicated cytokine pathways. Activities of key cytokine signaling pathways are modulated through complex mechanisms. For example, interleukin-2 is a central mediator of T-cell growth, and its signaling is finely regulated in part by the relative affinity of different combinations of its receptor components. Specifically, the high-affinity interleukin-2 receptor is composed of alpha (IL2RA, or CD25), beta (IL2RB), and gamma (IL2RG) (Table 1) . The cellular infiltrates characterizing inflammatory lesions are influenced by a diverse array of proinflammatory and antiinflammatory cytokines. In particular, a central proinflammatory, pathogenic role for subgroups of CD4+ type 1 helper T cells is under the control of interleukin-12 and has long been implicated in a variety of human and murine models of autoimmunity. An essential role for a related cytokine, interleukin-23, 53 has been shown in a variety of autoimmunity models, including mouse models of multiple sclerosis, inflammatory bowel disease, collagen-induced arthritis, and dermatitis. 54 Interleukin-23 is required for the expansion and survival of type 17 helper T cells, which have a key role in mediating mucosal immunity and defense against extracellular pathogens. These immunologic advances coincided with genetic discoveries of major association signals encompassing the interleukin-23 receptor (IL23R) to inflammatory bowel disease, 55 psoriasis, 56 and ankylosing spondylitis. 57 The interleukin-23 and interleukin-12 signaling pathways share components at their cytokines, receptors, and downstream signaling intermediates. 58 A striking number of these components are encoded by genes, variants of which are associated with autoimmunity (Fig. 4) . However, the intermediary signaling molecules are not specific to these cytokine pathways.
Innate Im muni t y a nd Microbi a l R e sp onse s
The human immune response to microbial pathogens has been shaped throughout evolutionary history by natural selection. It is likely that the increase in the prevalence of various autoimmune disorders that have been observed during the past century has occurred largely through changes in environmental and microbial exposures. Recent genetic advances have highlighted specific differences among individuals in innate immune-system responses that are characteristic of various subtypes of chronic inflammatory diseases. For example, one of the first genetic associations that was reported in complex genetic disorders was that between variants of NOD2 and Crohn's disease 59 ; this association represents the most substantial contributor to the overall heritability of Crohn's disease. NOD2 functions as an intracellular sensor for bacterial peptidoglycan, and variants associated with Crohn's disease are loss-of-function polymorphisms. Further implicating a primary role for innate immunity, variants of autophagy genes (e.g., ATG16L1) that target intracellular components, including microbes, to lysosomes have also been associated with Crohn's disease. 59 The increase in the prevalence of Crohn's disease during the past century may well reflect corresponding changes in the composition of the intestinal microbiota resulting from changes in hygiene, such as eradication of intestinal parasites. 60 A central role for the intestinal microbiota in inflammatory bowel disease provides the rationale for the therapeutic use of microbiome-altering probiotics. 61 However, the role of the intestinal microbiome is probably not limited to the intestinal immune system. Studies of mouse models of autoimmune diabetes suggest that host differences in the capacity to sense intestinal microbes 62 response and the intestinal microbiota will be an important focus of future research.
Gene s, En v ironmen t, a nd Au t oim muni t y
In addition to variability in bacterial responses, differences among individuals in antiviral responses contribute to autoimmunity. As noted above, interferon pathways mediate both autoimmunity and viral defense, 63 diabetes mellitus. 68 Previous infection with enteroviruses (a genera of picornaviruses) is more frequent in patients with newly diagnosed type 1 diabetes mellitus. 69 More broadly, it may be speculated that changing microbial exposures contributes to alterations in the prevalence of autoimmune diseases. With new genetic associations, we are now in position to address the mechanisms by which genetic variation controls the response to infection and thereby predisposes to the development of autoimmunity.
Beyond infectious agents, the specific environmental factors that contribute to autoimmunity have been extremely challenging to identify and include such factors as silica dust, cooking oil, sun exposure, and smoking. 70, 71 In some cases, the new genetics has made such studies more compelling and potentially more tractable by revealing interactions between environmental and genetic factors. Perhaps nowhere is this more evident than in the role of smoking as a risk factor for rheumatoid arthritis. Thus, although smoking is associated with a modest risk of rheumatoid arthritis (approximate risk ratio, 1.5), when variants of HLA and PTPN22 are taken into consideration, the combined risk in smokers is increased by more than a factor of 20. 72 Even more strikingly, this interaction between smoking and genetic factors is seen only in the major serologic subgroups of rheumatoid arthritis that have antibodies against particular citrullinated peptides (in 50 to 70% of patients with rheumatoid arthritis), whereas virtually no risk is observed for such patients who do not carry these antibodies. 73 Furthermore, there is evidence that smoking induces the appearance of citrullinated autoantigens in the lung, thus providing the beginnings of a causal pathway linking an environmental exposure (smoking, and possibly air pollution) to the production of pathogenic antibodies (anticitrullinated autoantibodies) in genetically predisposed persons. 74 This emphasizes that the power of environmental studies can be dramatically improved by focusing on specific genetic and phenotypic subgroups of a disease.
Implications of the New Genetics for Diagnosis and Tr e atment
The most obvious near-term potential use of genetic data is to improve diagnostic accuracy, as well as to permit disease stratification for risk assessment and treatment selection. However, most disease-associated alleles individually carry very modest degrees of risk. Indeed, for almost all autoimmune diseases, associations with the presence of HLA alleles are the strongest, and even these have not proved to be useful in clinical situations. Attempts to use data from genomewide association studies to determine drug response also have so far been disappointing. 75 Thus, it is likely that genetic data will need to be combined with other biomarkers to identify clinically meaningful subgroups of patients to guide the treatment of patients. Such an approach may be particularly useful for early detection of persons at risk for autoimmune disease, because serologic autoimmunity may be present for many years, 76 even though overt clinical disease develops in only a subgroup of such persons.
The new genetic data implicate new pathways that suggest new therapeutic targets. Indeed, many of the new biologic therapies appear to be appropriately matched to these pathways. These include inhibitors of tumor necrosis factor, anti-B-cell agents such as rituximab, and the fusion protein abatacept, which targets B7-CTLA4 interactions involved in T-cell activation (Fig. 3) . One of the best correlates between new therapies and genetics has been the use of anti-p40 monoclonal antibodies in patients with psoriasis, 77 which is characterized by an extremely strong interleukin-23 genetic signature (Fig. 4) . New therapeutic agents are emerging that target lymphocyte signaling through interferon inhibition, lymphocyte trafficking, or kinase inhibition. 78, 79 Given the multiplicity of gene associations implicating multiple disease pathways, future therapeutic advances may require the application of combination therapies. However, the blockade of multiple immune pathways is also likely to increase susceptibility to infectious complications. Although each genetic association represents a potentially new therapeutic target, future therapeutic advances will require increasingly refined and integrated models of disease pathogenesis. High-resolution comparison of association patterns across autoimmunity will soon be possible with data obtained from common genotyping platforms and may provide insight into which therapeutic targets should be prioritized for various disease subtypes.
There is much more to be learned about the genetics of autoimmunity; more than half the genetic contribution to autoimmunity still remains to be identified. The nature of this missing heritability remains a matter of intense debate. 80 
It may
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